Background—: Prospective data on the safety and efficacy of the wearable cardioverter defibrillator (WCD) in a real-world setting are lacking. The Prospective Registry of Patients Using the Wearable Defibrillator (WEARIT-II) Registry was designed to provide real-world data on the WCD as a strategy during a period of risk stratification. Methods and Results—: The WEARIT-II Registry enrolled 2000 patients with ischemic (n=805, 40%), or nonischemic cardiomyopathy (n=927, 46%), or congenital/inherited heart disease (n=268) prescribed WCD between August 2011 and February 2014. Clinical data, arrhythmia events, implantable cardioverter defibrillator implantation, and improvement in ejection fraction were captured. The median age was 62 years; the median ejection fraction was 25%. The median WCD wear time was 90 days, with median daily use of 22.5 hours. There was a total of 120 sustained ventricular tachyarrhythmias in 41 patients, of whom 54% received appropriate WCD shock. Only 10 patients (0.5%) received inappropriate WCD therapy. The rate of sustained ventricular tachyarrhythmias by 3 months was 3% among patients with ischemic cardiomyopathy and congenital/inherited heart disease, and 1% among nonischemic patients ( P =0.02). At the end of WCD use, 840 patients (42%) were implanted with an implantable cardioverter defibrillator. The most frequent reason not to implant an implantable cardioverter defibrillator following WCD use was improvement in ejection fraction. Conclusions—: The WEARIT-II Registry demonstrates a high rate of sustained ventricular tachyarrhythmias at 3 months in at-risk patients who are not eligible for an implantable cardioverter defibrillator, and suggests that the WCD can be safely used to protect patients during this period of risk assessment.
1 November 2017 in JACC: Clinical Electrophysiology
Background: Previous studies have shown conflicting results regarding the benefit of cardiac resynchronization therapy ( CRT ) by sex and QRS duration. Methods and Results: In the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy ( MADIT ‐ CRT ), we evaluated long‐term clinical outcome of heart failure ( HF ) or death, death, and HF alone by sex and QRS duration (dichotomized at 150 ms) in left bundle‐branch block patients with CRT with defibrillator backup ( CRT ‐D) versus implantable cardioverter‐defibrillator ( ICD ) only. There were 394 women (31%) and 887 men with left bundle‐branch block. During the median follow‐up of 5.6 years, women derived greater clinical benefit from CRT ‐D compared with implantable cardioverter‐defibrillator only, with a significant 71% reduction in HF or death (hazard ratio [ HR ] 0.29, P <0.001) and a 77% reduction in HF alone ( HR 0.23, P <0.001) compared with men, who had a 41% reduction in HF or death ( HR 0.59, P <0.001) and a 50% reduction in HF alone ( HR 0.50, P <0.001) (all sex‐by‐treatment interaction P <0.05). Men and women had similar reduction in long‐term mortality with CRT ‐D versus implantable cardioverter‐defibrillator only (men: HR 0.70, P =0.03; women: HR 0.59, P =0.04). The incremental benefit of CRT ‐D in women for HF or death and HF alone was consistent with QRS 150 ms. Conclusions: During long‐term follow‐up of mild HF patients with left ventricular dysfunction and wide QRS , both women and men with left bundle‐branch block derived sustained benefit from CRT ‐D versus implantable cardioverter‐defibrillator only, with significant reduction in HF or death, HF alone, and all‐cause mortality regardless of QRS duration. There is an incremental benefit with CRT ‐D in women for the end points of HF or death and HF alone. Clinical Trial Registration: URL: https://clinicaltrials.gov/ . Unique identifiers: NCT00180271, NCT01294449, and NCT02060110.